Amrit Ray
Director/Board Member at ULTRAGENYX PHARMACEUTICAL INC.
Net worth: 573 353 $ as of 31/03/2024
Profile
Amrit Ray is an Independent Director at Ultragenyx Pharmaceutical, Inc., a Director at Everylife Foundation for Rare Diseases, a Director at CorEvitas LLC, and an Independent Director at Fortrea Holdings, Inc. He was previously the Chief Medical Officer at Johnson & Johnson, the Global President-Research & Development at Pfizer Inc., and the Chief Patient Officer at Biohaven Pharmaceuticals, Inc. Dr. Ray received his undergraduate and doctorate degrees from The University of Edinburgh and his MBA from Tuck School of Business at Dartmouth.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 07/06/2023 | 12,280 ( 0.01% ) | 573 353 $ | 31/03/2024 |
Amrit Ray active positions
| Companies | Position | Start |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Director/Board Member | 19/04/2022 |
| FORTREA HOLDINGS INC. | Director/Board Member | 29/06/2023 |
CorEvitas LLC
 CorEvitas LLC BiotechnologyHealth Technology CorEvitas LLC engages in the provision of medical research services. It offers real-world evidence solutions; safety; patient engagement; precision medicine biorepository. The company was founded by Joel Kremer in 2001 and is headquartered in Waltham, MA. | Director/Board Member | 03/08/2021 |
Everylife Foundation for Rare Diseases
 Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services EveryLife Foundation for Rare Diseases is a non-profit organization that aims to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy. The non-profit company is based in Novato, CA and was founded by Emil D. Kakkis. The foundation provides training, education, resources, and opportunities to make patient voices heard, with the belief that activating the patient advocate can change public policy and save lives. | Director/Board Member | - |
Former positions of Amrit Ray
| Companies | Position | End |
|---|---|---|
Biohaven Pharmaceuticals, Inc.
 Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01/12/2022 |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
| JOHNSON & JOHNSON | Chief Tech/Sci/R&D Officer | - |
Training of Amrit Ray
| The University of Edinburgh | Doctorate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| PFIZER, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| FORTREA HOLDINGS INC. | Commercial Services |
| Private companies | 3 |
|---|---|
Everylife Foundation for Rare Diseases
Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services EveryLife Foundation for Rare Diseases is a non-profit organization that aims to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy. The non-profit company is based in Novato, CA and was founded by Emil D. Kakkis. The foundation provides training, education, resources, and opportunities to make patient voices heard, with the belief that activating the patient advocate can change public policy and save lives. | Commercial Services |
CorEvitas LLC
CorEvitas LLC BiotechnologyHealth Technology CorEvitas LLC engages in the provision of medical research services. It offers real-world evidence solutions; safety; patient engagement; precision medicine biorepository. The company was founded by Joel Kremer in 2001 and is headquartered in Waltham, MA. | Health Technology |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
- Stock Market
- Insiders
- Amrit Ray
